의료진프로필

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Nastoupil, LJ; Hess, G; Pavlovsky, MA; Danielewicz, I; Freeman, J; Garcia-Sancho, AM; Glazunova, V; Grigg, A; Hou, JZ; Janssens, A; Kim, SJ; Masliak, Z; Mckay, P; Merli, F; Munakata, W; Nagai, H; Özcan, M; Preis, M; Wang, TY; Rowe, M; Tamegnon, M; Cir, R; Henninger, T; Curtis, M; Caces, DB; Thieblemont, C; Salles, G

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma

Yoon, SE; Park, S; Cho, J; Ryu, KJ; Yandava, B; Lee, S; Kim, SJ; Kim, WS

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation

Kim, SJ; Jo, JC; Yoon, DH; Yang, DH; Yoon, SE; Lee, GW; Kong, JH; Park, Y; Kang, KW; Lee, HS; Oh, SY; Shin, HJ; Lee, WS; Choi, YS; Jeong, SH; Kim, MK; Kang, HJ; Yi, JH; Lim, SN; Yhim, HY; Do, YR; Yun, HJ; Eom, HS; Lee, MH; Suh, C; Kim, WS

Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study

Park, S; Kim, JH; Kim, S; Kang, J; Moon, S; Kim, SJ; Shin, JY

Clinical relevance of deep learning models in predicting the onset timing of cancer pain exacerbation

Bang, YH; Choi, YH; Park, M; Shin, SY; Kim, SJ

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis

Kim, J; Cho, JHY; Yoon, SE; Kim, WS; Kim, SJ

Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis

Park, YJ; Lee, JH; Kim, D; Choi, JO; Kim, SJ; Kim, K; Choi, JY

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

San-Miguel, J; Dhakal, B; Yong, K; Spencer, A; Anguille, S; Mateos, MV; de Larrea, CF; Martinez-Lopez, J; Moreau, P; Touzeau, C; Leleu, X; Avivi, I; Cavo, M; Ishida, T; Kim, SJ; Roeloffzen, W; van de Donk, NWCJ; Dytfeld, D; Sidana, S; Costa, LJ; Oriol, A; Popat, R; Khan, AM; Cohen, YC; Ho, PJ; Griffin, J; Lendvai, N; Lonardi, C; Slaughter, A; Schecter, JM; Jackson, CC; Connors, K; Li, K; Zudaire, E; Chen, DN; Gilbert, J; Yeh, T; Nagle, S; Florendo, E; Pacaud, L; Patel, N; Harrison, SJ; Einsele, H

Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation

Baek, DW; Moon, JH; Lee, JH; Kang, KW; Lee, HS; Eom, HS; Lee, ENY; Lee, JH; Lee, JO; Park, SK; Kim, SJ; Yoo, KH; Yoon, SS; Koh, Y; Kang, HJ; Won, JH; Lyu, CJ; Hahn, SM; Lee, JH; Park, JS; Jo, JC; Mun, YC; Yang, DH; Song, GY; Lim, SN; Sohn, SK

Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment

Jin, HY; Jin, MY; Lim, CH; Choi, JY; Kim, SJ; Lee, KH

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma

Lee, H; Yoon, SE; Kim, SJ; Kim, WS; Cho, JH

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma

Lee, YP; Yoon, SE; Cho, J; Ko, YH; Oh, D; Ahn, YC; Kim, WS; Kim, SJ

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma

Yoon, SE; Kang, W; Choi, S; Park, Y; Chalita, M; Kim, H; Lee, JH; Hyun, DW; Ryu, KJ; Sung, H; Lee, JY; Bae, JW; Kim, WS; Kim, SJ

A Novel Transthyretin Gene Mutation in Hereditary Transthyretin Amyloidosis: A Case Series of Met13dup Patients

Jeon, K; Kim, D; Park, M; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma

Jeon, Y; Yoon, SE; Cho, JH; Kim, SJ; Kim, WS

A novel prognostic model based on pretreatment serum albumin and ECOG PS for primary CNS lymphoma: an international, multi-center study

Wei, L; Gao, YT; Prochazka, KT; Liu, RQ; Wang, L; Liu, BY; He, YZ; Bertero, L; Pellerino, A; Cassoni, P; Tamagnone, L; Deutsch, AJ; Zhan, HE; Lai, J; Kim, SJ; You, H

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)

Cho, HYW; Yoon, DH; Shin, DY; Koh, Y; Yoon, SS; Kim, SJ; Do, YR; Lee, GW; Kwak, JY; Park, Y; Kim, MK; Kang, HJ; Yi, JH; Yoo, KH; Lee, WS; Park, BB; Jo, JC; Eom, HS; Kim, HJ; Jeong, SH; Won, YW; Sohn, BS; Kwon, JH; Suh, C; Kim, WS

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections

Yang, J; Won, G; Baek, JY; Lee, YH; Kim, H; Huh, K; Cho, SY; Kang, CI; Chung, DR; Peck, KR; Lee, KW; Park, JB; Yoon, SE; Kim, SJ; Kim, WS; Yim, MS; Kim, K; Hyeon, S; Kim, BC; Lee, YK; Ko, JH

In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas

Kim, JJ; Kim, HY; Choi, Z; Hwang, SY; Jeong, H; Choi, JR; Yoon, SE; Kim, WS; Kim, SH; Kim, HJ; Shin, SY; Lee, ST; Kim, SJ

Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea

Kim, HR; Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K

TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients

Cho, J; Kim, E; Yoon, SE; Kim, SJ; Kim, WS

Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma

Lee, J; Han, JH; Lee, CH; Park, HS; Min, SK; Lee, H; Cho, U; Yoon, SE; Kim, SJ; Kim, WS; Cho, JH

Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas

Kim, SJ; Kim, YJ; Yoon, SE; Ryu, KJ; Park, B; Park, D; Cho, D; Kim, HY; Cho, J; Ko, YH; Park, WY; Kim, WS

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma

Jeong, SY; Yoon, SE; Cho, D; Kang, ES; Cho, J; Kim, WS; Kim, SJ

A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum beta-2 Microglobulin to PINK

Kang, S; Cho, H; Kim, S; Lee, K; Kang, EH; Park, JS; Lee, YS; Park, CS; Go, H; Huh, J; Ryu, JS; Lee, SW; Kim, SJ; Kim, WS; Yoon, SE; Ko, YH; Suh, C

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts

Yi, JH; Jeong, SH; Kim, SJ; Yoon, DH; Kang, HJ; Koh, Y; Kim, JS; Lee, WS; Yang, DH; Do, YR; Kim, MK; Yoo, KH; Choi, YS; Yun, WJ; Park, Y; Jo, JC; Eom, HS; Kwak, JY; Shin, HJ; Park, BB; Yi, SY; Kwon, JH; Oh, SY; Kim, HJ; Sohn, BS; Won, JH; Hong, DS; Lee, HS; Lee, GW; Suh, C; Kim, WS

A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea

Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain

Cho, J; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis

Yi, JH; Kim, SJ; Lee, JO; Lee, GW; Kwak, JY; Eom, HS; Jo, JC; Choi, YS; Oh, SY; Kim, WS

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma

Kim, SJ; Ryu, KJ; Park, B; Yoon, SE; Cho, J; Park, Y; Kim, WS

Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma

Yoon, SE; Cho, J; Kim, YJ; Kim, SJ; Kim, WS

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged >= 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study

Jeong, SH; Kim, SJ; Yoon, DH; Park, Y; Kang, HJ; Koh, Y; Lee, GW; Lee, WS; Yang, DH; Do, YR; Kim, MK; Yoo, KH; Choi, YS; Yun, HJ; Yi, JH; Jo, JC; Eom, HS; Kwak, JY; Shin, HJ; Park, BB; Hyun, SY; Yi, SY; Kwon, JH; Oh, SY; Kim, HJ; Sohn, BS; Won, JH; Kim, SH; Lee, HS; Suh, C; Kim, WS

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma

Kim, HY; Yoo, IY; Lim, DJ; Kim, HJ; Kim, SH; Yoon, SE; Kim, SJ; Cho, D; Kim, K

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis

Lee, YP; Lee, MS; Yoon, SE; Cho, JH; Bang, YH; Shim, JH; Kim, WS; Kim, SJ

Lymphoma total lesion glycolysis leads to hyperlactatemia and reduction of brain glucose utilization

Yi, HK; Yoo, J; Kim, SJ; Choi, JY; Lee, KH

Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis

Kwon, S; Jeong, WK; Park, JH; Kim, J; Cho, EB; Seok, JM; Kim, SJ; Kim, K; Jeon, ES; Min, JH; Kim, BJ

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Wang, MCL.; Jurczak, W; Jerkeman, M; Trotman, J; Zinzani, PL; Belada, D; Boccomini, C; Flinn, IW; Giri, P; Goy, A; Hamlin, PA; Hermine, O; Hernandez-Rivas, JA; Hong, XA; Kim, SJ; Lewis, D; Mishima, Y; Ozcan, M; Perini, GF; Pocock, C; Song, YQ; Spurgeon, SE; Storring, JM; Walewski, J; Zhu, J; Qin, R; Henninger, T; Deshpande, S; Howes, A; Le Gouill, S; Dreyling, M

Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis

Bak, M; Kim, D; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma

Lee, YP; Yoon, SE; Cho, J; Ko, YH; Jo, H; Kim, SJ; Kim, WS

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma

Yoon, SE; Kim, YJ; Shim, JH; Park, D; Cho, J; Ko, YH; Park, WY; Mun, YC; Lee, KE; Cho, D; Kim, WS; Kim, SJ

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma

Bang, YH; Shim, JH; Ryu, KJ; Kim, YJ; Choi, ME; Yoon, SE; Cho, J; Park, B; Park, WY; Kim, WS; Kim, SJ

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells

Lee, YH; Lee, HJ; Kim, HC; Lee, Y; Nam, SK; Hupperetz, C; Ma, JSY; Wang, XX; Singer, O; Kim, WS; Kim, SJ; Koh, Y; Jung, I; Kim, CH

Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis

Yoon, SE; Jo, H; Kang, ES; Cho, D; Cho, J; Kim, WS; Kim, SJ

Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma

Kim, N; Lim, DH; Yoon, SE; Kim, SJ; Kim, WS

Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study

Kang, D; Yoon, SE; Shin, D; Lee, J; Hong, YS; Lee, SK; Lee, JE; Park, YH; Ahn, JS; Guallar, E; Kim, WS; Lee, J; Kim, SJ; Cho, J

A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review

Kim, JA; Kim, HY; Kim, SJ; Kim, HJ; Kim, SH

Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma

Jung, SH; Lee, JJ; Song, GY; Lee, HS; Kim, SJ; Yoon, SE; Kim, K

tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method

Lee, S; Ju, S; Kim, SJ; Choi, JO; Kim, K; Kim, D; Jeon, ES; Lee, C

Prognostic significance of serum beta 2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified

Kim, HD; Cho, H; Sohn, BS; Park, CS; Huh, J; Ryu, JS; Lee, SW; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS; Suh, C

Obesity-Independent Association between Glycemic Status and the Risk of Hematologic Malignancy: A Nationwide Population-Based Longitudinal Cohort Study

Kang, J; Jin, SM; Kim, SJ; Kim, D; Han, K; Jeong, SM; Chang, J; Rhee, SY; Choi, T; Shin, DW

Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma

Lim, CH; Yoon, SE; Kim, WS; Lee, KH; Kim, SJ

Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis

Kim, J; Cho, J; Byeon, S; Kim, WS; Kim, SJ

Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis

Kim, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing

Cho, J; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS

A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups

Gao, YT; Wei, L; Kim, SJ; Wang, L; He, YZ; Zheng, YF; Bertero, L; Pellerino, A; Cassoni, P; Tamagnone, L; Theresa, PK; Deutsch, A; Zhan, HE; Lai, J; Wang, Y; You, H

Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34(+) cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation

Kim, SM; Kim, HY; Kim, SJ; Jang, JH; Kim, K; Kim, WS; Jung, CW; Cho, D; Kang, ES

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Kim, WS; Oki, Y; Kim, SJ; Yoon, SE; Ardeshna, KM; Lin, Y; Ruan, J; Porcu, P; Brammer, JE; Jacobsen, ED; Yoon, DH; Suh, C; Suarez, F; Radford, J; Budde, LE; Kim, JS; Bachy, E; Lee, HJ; Bollard, CM; Jaccard, A; Kang, HJ; Inman, S; Murray, M; Combs, KE; Lee, DIY; Advani, R; Gunter, KC; Rooney, CM; Heslop, HE

Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

Lee, YP; Yoon, SE; Song, YQ; Kim, SJ; Yoon, DH; Chen, TY; Koh, YI; Kang, KW; Lee, HS; Wei, KTK; Lim, ST; Poon, M; Irawan, C; Zhao, WL; Do, YR; Lee, MH; Ng, SC; Lee, WS; Guo, Y; Zhang, HL; Kang, HJ; Yun, HJ; Kim, HJ; Lung, DTC; Kwak, JY; Han, JJ; Mun, YC; Oh, SY; Shim, H; Kwon, JH; Sohn, BS; Park, SK; Jo, JC; Ko, YH; Jun, Z; Kim, WS

Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy

Kim, N; Lim, HD; Yoon, SE; Kim, SJ; Kim, WS

Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum beta 2-microglobulin Levels

Kim, HD; Cho, H; Kim, S; Lee, K; Kang, EH; Park, JS; Park, CS; Huh, J; Ryu, JS; Lee, SW; Yoon, DH; Kim, SJ; Ko, YH; Kim, WS; Suh, C

Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis

Kim¹, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma

Lee¹, BH; Park, Y; Kim, JH; Kang, KW; Lee, SJ; Kim, SJ; Kim, BS

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

Lee¹, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas

Yoon¹, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma

Lee¹, JY; Kim, JH; Bang, H; Cho, J; Ko, YH; Kim, SJ; Kim, WS

Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia

Cho¹, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ

Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial

Yhim¹, HY; Kim, T; Kim, SJ; Shin, HJ; Koh, Y; Kim, JS; Park, J; Park, GS; Kim, WS; Moon, JH; Yang, DH

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation

Park¹, YJ; Hyun, SH; Moon, SH; Lee, KH; Min, BH; Lee, JH; Kim, WS; Kim, SJ; Choi, JY

Metabolic activity of extranodal NK/T cell lymphoma on F-18-FDG PET/CT according to immune subtyping

Lim¹, CH; Yoon, SE; Kim, SJ; Cho, J; Ko, YH; Lee, KH; Kim, WS

Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis

Lee¹, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months

Yoon¹, SE; Cho, J; Kim, WS; Kim, SJ

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis

Yi¹, JH; Kim, SJ; Yoon, DH; Suh, C; Chang, MH; Yang, DH; Jo, JC; Hyun, SY; Eom, HS; Lee, JO; Kwon, JH; Han, SH; Lee, SS; Kwak, JY; Kim, SH; Kim, DS; Lee, JH; Oh, SY; Ryoo, HM; Kim, HJ; Kim, WS

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lee¹, B; Lee, H; Cho, J; Yoon, SE; Kim, SJ; Park, WY; Kim, WS; Ko, YH

Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma

Kim¹, SJ; Kang, D; Park, Y; Mun, YC; Kim, K; Kim, JS; Min, CK; Cho, J

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma

Kang¹, JH; Lee, SH; Lee, J; Choi, M; Cho, J; Kim, SJ; Kim, WS; Ko, YH; Yoo, HY

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma an open-label phase 2 study

Kim¹, SJ; Lim, JQ; Laurensia, Y; Cho, J; Yoon, SE; Lee, JY; Ryu, KJ; Ko, YH; Koh, Y; Cho, D; Lim, ST; Enemark, MB; D'amore, F; Bjerre, M; Ong, CK; Kim, WS

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma

Ryu¹, KJ; Lee, JY; Choi, ME; Yoon, SE; Cho, J; Ko, YH; Shim, JH; Kim, WS; Park, C; Kim, SJ

Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy

Jeong¹, SM; Choi, T; Kim, D; Han, K; Kim, SJ; Rhee, SY; Giovannucci, EL; Shin, DW

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma

Song¹, GY; Yoon, DH; Suh, C; Moon, JH; Baek, DW; Kim, JS; Lee, GW; Yi, JH; Park, Y; Jung, KS; Kim, SJ; Yang, DH; Kim, WS

Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Cho¹, I; Yoon, N; Hyeon, J; Sim, J; Yoo, HY; Kim, SJ; Kim, WS; Ko, YH

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

Kim¹, H; Jeong, H; Yamaguchi, M; Sohn, I; Yoon, SE; Byeon, S; Hur, JY; Koh, Y; Yoon, SS; Kim, EJ; Oguchi, M; Miyazaki, K; Taguchi, S; Yoon, DH; Cho, J; Ko, YH; Kim, SJ; Suzuki, R; Kim, WS

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Yhim¹, HY; Eshet, Y; Metser, U; Lim, CH; Lajkosz, K; Isaev, K; Cooper, M; Prica, A; Kukreti, V; Bhella, S; Lang, N; Lee, KH; Xu, W; Hodgson, D; Tsang, R; Yoon, SE; Kim, SJ; Kim, WS; Crump, M; Kuruvilla, J; Kridel, R

Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis

Yoo¹, IY; Bang, SH; Lim, DJ; Kim, SJ; Kim, K; Kim, HJ; Kim, SH; Cho, D

Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners

Kim¹, IR; Jang, SY; Shin, HS; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Kim, SJ; Kim, K; Kim, WS; Lee, CH; Kang, D; Cho, J

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis A Multicenter Phase 2 Trial

Yhim¹, HY; Yoon, DH; Kim, SJ; Yang, DH; Eom, HS; Ha Kim, K; Park, Y; Kim, JS; Kim, HJ; Suh, C; Kim, WS; Kwak, JY

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Lim¹, JQ; Huang, DC; Tang, T; Tan, D; Laurensia, Y; Peng, RJ; Wong, EKY; Cheah, DMZ; Chia, BKH; Iqbal, J; Grigoropoulos, NF; Nairismagi, ML; Ng, CCY; Rajasegaran, V; Hong, HM; Kim, SJ; Cho, J; Tse, E; Mow, B; Cai, QC; Poon, L; Cai, QQ; Tan, J; Chan, JY; Lim, JX; Goh, YT; Phipps, C; Rotzschke, O; Cheng, CL; Ha, JCH; Khoo, LP; Loh, YSM; Au-Yeung, R; Chan, TSY; Kwong, YL; Hwang, W; Kim, WS; Bei, JX; Lin, TY; Ong, CK; Lim, ST

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

Song¹, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ

Asian variant of intravascular large B-cell lymphoma a comparison of clinical features based on involvement of the central nervous system

Yoon¹, SE; Kim, WS; Kim, SJ

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis developing a nomogram-based prognostic model

Lee¹, BH; Park, Y; Kim, JH; Kang, KW; Lee, SJ; Kim, SJ; Kim, BS

Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization

Kang¹, KW; Lee, SJ; Kim, JH; Lee, BH; Kim, SJ; Park, Y; Kim, BS

Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era

Song¹, GY; Yoon, SE; Kim, SJ; Kim, JS; Koh, Y; Moon, JH; Oh, SY; Lee, HS; Shin, HJ; Do, YR; Lee, WS; Kim, DS; Park, Y; Yhim, HY; Yang, DH

Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas

Hur¹, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

Yoon¹, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS

Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

Yi¹, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study

Yoon¹, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ

Isolation of Small Extracellular Vesicles From Human Serum Using a Combination of Ultracentrifugation With Polymer-Based Precipitation

Ryu¹, KJ; Lee, JY; Park, C; Cho, D; Kim, SJ

Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

Fox¹, CP; Civallero, M; Ko, YH; Manni, M; Skrypets, T; Pileri, S; Kim, SJ; Cabrera, ME; Shustov, AR; Chiattone, CS; Horwitz, SM; Dlouhy, I; Spina, M; Hitz, F; Montoto, S; Nagler, A; Martinez, V; De Souza, CA; Fernandez-Alvarez, R; Ballova, V; Gabus, R; Inghirami, G; Federico, M; Kim, WS

Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression

Cho¹, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Kim¹, SJ; Yoon, DH; Kim, JS; Kang, HJ; Lee, HW; Eom, HS; Hong, JY; Cho, J; Ko, YH; Huh, J; Yang, WI; Park, WS; Lee, SS; Suh, C; Kim, WS

Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk

Witalis¹, M; Chang, J; Zhong, MC; Bouklouch, Y; Panneton, V; Li, JN; Buch, T; Kim, SJ; Kim, WS; Ko, YH; Veillette, A; Suh, WK

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Kroschinsky¹, F; Middeke, JM; Janz, M; Lenz, G; Witzens-Harig, M; Bouabdallah, R; La Rosee, P; Viardot, A; Salles, G; Kim, SJ; Kim, TM; Ottmann, O; Chromik, J; Quinson, AM; von Wangenheim, U; Burkard, U; Berk, A; Schmitz, N

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

Yoon¹, DH; Cao, JN; Chen, TY; Izutsu, K; Kim, SJ; Kwong, YL; Lin, TY; Thye, LS; Xu, B; Yang, DH; Kim, WS

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Cho¹, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion

Ryu¹, D; Kim, SJ; Hong, Y; Jo, A; Kim, N; Kim, HJ; Lee, HO; Kim, K; Park, WY

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma

Won¹, YW; Lee, H; Eom, HS; Kim, JS; Suh, C; Yoon, DH; Hong, JY; Kang, HJ; Lee, JH; Kim, WS; Kim, SJ; Lee, WS; Chang, MH; Do, YR; Yi, JH; Kim, I; Won, JH; Kim, K; Oh, SY; Jo, JC

Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report

Jo¹, JC; Kim, SJ; Lee, HS; Eom, HS; Lee, SI; Park, Y; Lee, JO; Lee, Y; Yhim, HY; Yang, DH; Byun, JM; Kang, HJ; Kim, HJ; Shin, HJ; Yoo, KH; Suh, C

Impact of fear of cancer recurrence on survival among lymphoma patients

Kim¹, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J

Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis

Choi¹, KH; Lee, JM; Kim, SR; Kim, D; Choi, JO; Kim, SJ; Kim, K; Kim, JS; Koo, BK; Jeon, ES

Tc-99m-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis Potential clinical implications

Lee¹, JH; Kim, K; Choi, JO; Kim, SJ; Jeon, ES; Choi, JY

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Lee¹, HS; Kim, K; Kim, SJ; Lee, JJ; Kim, I; Kim, JS; Eom, HS; Yoon, DH; Suh, C; Shin, HJ; Mun, YC; Kim, MK; Lim, SN; Choi, CW; Kang, HJ; Yoon, SS; Min, CK

Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors

Im¹, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance

Kim¹, HK; Kang, W; Sinn, DH; Lee, JH; Kim, WS; Kim, SJ

Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults

Choi¹, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Lee¹, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma

Yi¹, JH; Lee, GW; Do, YR; Jung, HR; Hong, JY; Yoon, DH; Suh, C; Choi, YS; Yi, SY; Sohn, BS; Kim, BS; Oh, SY; Park, J; Jo, JC; Lee, SS; Oh, YH; Kim, SJ; Kim, WS

Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016 An observational study

Sim¹, J; Takayama, T; Cho, J; Kim, SJ; Kim, WS; Ree, HJ; Ko, YH

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Kim¹, SJ; Yoon, DH; Kang, HJ; Hong, JY; Lee, HS; Oh, SY; Shin, HJ; Kong, JH; Yi, JH; Sakamoto, K; Ko, YH; Huh, J; Lee, SS; Takeuchi, K; Shin, DY; Suh, C; Kim, WS

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study

Tan¹, KM; Chia, B; Lim, JQ; Khoo, LP; Cheng, CL; Tan, L; Poon, E; Somasundaram, N; Farid, M; Tang, TPL; Tao, M; Cheah, DMZ; Laurensia, Y; Pang, JWL; Song, T; Tan, J; Huang, DC; Kim, SJ; Kim, WS; Ong, CK; Lim, ST; Chan, JY

Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma

Park¹, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores

Huh¹, S; Oh, SY; Lee, S; Lee, JH; Kim, SH; Lee, GW; Kim, SJ; Kim, WS; Lee, HS; Jo, JC; Kim, MJ; Kwon, JH; Kim, HJ

Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma

Shin¹, J; Ko, YH; Oh, SY; Yoon, DH; Lee, JO; Kim, JS; Park, Y; Shin, HJ; Kim, SJ; Won, JH; Yoon, SS; Kim, WS; Koh, Y

Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis

Park¹, MS; Yoo, IY; Kim, HJ; Kim, SH; Kim, SJ; Cho, D

Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma

Li Chan¹, EH; Koh, LP; Lee, J; De Mel, S; Jeyasekharan, A; Liu, X; Tang, T; Lim, ST; Tao, M; Quek, R; Ras, MFB; Lee, YS; Diong, C; Tan, D; Kim, SJ; Chee, YL; Poon, LM

Prognostic values of novel biomarkers in patients with AL amyloidosis

Kim¹, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES

A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study

Park¹, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK

Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes

Shin¹, SH; Kim, YJ; Lee, D; Cho, D; Ko, YH; Cho, J; Park, WY; Park, D; Kim, SJ; Kim, WS

Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis

Kim¹, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Kim¹, SJ; Hyeon, J; Cho, I; Ko, YH; Kim, WS

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma

Lee¹, H; Oh, D; Yang, K; Ko, YH; Ahn, YC; Kim, WS; Kim, SJ

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing <= 70 kg

Kuruvilla¹, J; Tzeng, CH; Cho, SG; Kim, SJ; Tang, JL; Su, YM; Wu, JY; Vargo, R; Cheverton, P

Validation of the Marginal Zone Lymphoma International Prognostic Index

Hong¹, J; Cho, J; Ko, YH; Kim, SJ; Kim, WS

Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma

Yi¹, JH; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma

Lim¹, SW; Ryu, KJ; Lee, H; Ko, YH; Kim, WS; Kim, SJ

A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score

Yhim¹, HY; Park, Y; Han, YH; Kim, S; Kang, SR; Moon, JH; Jeong, JH; Shin, HJ; Kim, K; Choi, YS; Kim, K; Kim, MK; Kong, E; Kim, DS; Eo, JS; Lee, JH; Kang, DY; Lee, WS; Lee, SM; Do, YR; Ham, JS; Kim, SJ; Kim, WS; Choi, JY; Yang, DH; Kwak, JY

Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma

Kim¹, SJ; Shu, C; Ryu, KJ; Kang, D; Cho, J; Ko, YH; Lee, SY; Guallar, E; Zhao, W; Kim, WS

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Jeong¹, SH; Song, HN; Park, JS; Yang, DH; Koh, Y; Yoon, SS; Lee, HW; Eom, HS; Won, JH; Kim, WS; Kim, SJ

The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms

Hwang¹, HS; Yoon, DH; Hong, JY; Park, CS; Lee, YS; Ko, YH; Kim, SJ; Kim, WS; Suh, C; Huh, J

Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients

Ryu¹, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study

Kang¹, D; Cho, J; Kim, IR; Kim, MK; Kim, WS; Kim, SJ

Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study

Oh¹, SY; Kim, WS; Kang, HJ; Lee, JH; Huh, S; Kim, S; Yoon, DH; Hong, JY; Lee, WS; Kim, HJ; Won, JH; Park, BB; Lee, SI; Suh, C

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy

Cho¹, H; Yoon, DH; Kim, KP; Bae, KS; Kim, WS; Eom, HS; Kim, JS; Hong, JY; Kim, SJ; Lee, H; Kim, SJ; Suh, C

Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement

Hyeon¹, J; Lee, B; Shin, SH; Yoo, HY; Kim, SJ; Kim, WS; Park, WY; Ko, YH

Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma

Cho¹, J; Kim, SJ; Park, S; Yoo, KH; Ki, CS; Ko, Y; Kim, WS

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis

Hong¹, JY; Yoon, DH; Suh, C; Kim, WS; Kim, SJ; Jo, JC; Kim, JS; Lee, WS; Oh, SY; Park, Y; Kim, SY; Lee, MH; Lee, HS; Do, YR

Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data

Fan¹, J; Lee, HO; Lee, S; Ryu, DE; Lee, S; Xue, C; Kim, SJ; Kim, K; Barkas, N; Park, PJ; Park, WY; Kharchenko, PV

Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study

Yoo¹, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker

Kang¹, KW; Jung, JH; Hur, W; Park, J; Shin, H; Choi, B; Jeong, H; Kim, DS; Yu, ES; Lee, SR; Sung, HJ; Kim, SJ; Choi, CW; Kim, HK; Hong, S; Park, JH; Choi, Y; Park, Y; Kim, BS

A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System

Jung¹, SH; Kim, K; Kim, JS; Kim, SJ; Cheong, JW; Kim, SJ; Ahn, JS; Ahn, SY; Yang, DH; Kim, HJ; Lee, JJ

Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy

Yamaguchi¹, M; Suzuki, R; Kim, SJ; Ko, YH; Oguchi, M; Asano, N; Miyazaki, K; Terui, Y; Kubota, N; Maeda, T; Kobayashi, Y; Amaki, J; Soejima, T; Saito, B; Shimoda, E; Fukuhara, N; Tsukamoto, N; Shimada, K; Choi, I; Utsumi, T; Ejima, Y; Kim, WS; Katayama, N

Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell

Lee¹, GI; Oh, D; Kim, WS; Kim, SJ; Ko, YH; Woo, KI; Kim, YD; Ahn, YC

Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay

Takayama¹, T; Shin, S; Kang, S; Kim, SJ; Kim, WS; Ko, YH

Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma

Kang¹, KW; Lee, SR; Kim, DS; Yu, ES; Sung, HJ; Kim, SJ; Choi, CW; Park, Y; Kim, BS

CXCR4 can induce PI3K delta inhibitor resistance in ABC DLBCL

Kim¹, JH; Kim, WS; Ryu, KJ; Kim, SJ; Park, C

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma

Kwong¹, YL; Kim, SJ; Tse, E; Oh, SY; Kwak, JY; Eom, HS; Do, YR; Mun, YC; Lee, SR; Shin, HJ; Suh, C; Chuang, SS; Lee, YS; Lim, ST; Izutsu, K; Suzuki, R; Relander, T; d'Amore, F; Schmitz, N; Jaccard, A; Kim, WS

Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors

Cho¹, J; Kang, D; Kim, IR; Kim, WS; Ferrell, B; Kim, SJ

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

Hong¹, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers

Tang¹, T; Khoo, LP; Lim, C; Ham, JS; Kim, SJ; Hong, HM; Phipps, C; Lee, YS; Tao, M; Quek, R; Farid, M; Lin, TY; Kim, WS; Lim, ST

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

Hong¹, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy

Park¹, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma

Hong¹, J; Kim, SJ; Chang, MH; Kim, JA; Kwak, JY; Kim, JS; Yoon, DH; Lee, WS; Do, YR; Kang, HJ; Eom, HS; Park, Y; Won, JH; Mun, YC; Kim, HJ; Kwon, JH; Kong, JH; Oh, SY; Lee, S; Bae, SH; Yang, DH; Jun, HJ; Lee, HS; Yun, HJ; Lee, SI; Kim, MK; Yi, JH; Lee, JH; Kim, WS; Suh, C

Mycobacterium abscessus glossitis

Ko¹, JH; Kang, CI; Cho, SY; Ha, YE; Lee, NY; Kim, SJ; Chung, DR; Peck, KR; Song, JH

Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

Lim¹, SH; Hong, JY; Lim, ST; Hong, H; Arnoud, J; Zhao, W; Yoon, DH; Tang, T; Cho, J; Park, S; Ko, YH; Kim, SJ; Suh, C; Lin, T; Kim, WS

Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma

Ham¹, JS; Park, HY; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea

Kim¹, HS; Kim, HJ; Kim, SH; Choi, JY; Ko, YH; Kim, WS; Jung, CW; Kim, SJ

Macrophage inflammatory protein 1 alpha (MIP-1) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma

Kim¹, HS; Ryu, KJ; Ko, YH; Kim, HJ; Kim, SH; Kim, WS; Kim, SJ

Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma

Moon SH1¹, Lee AY1, Kim WS2, Kim SJ2, Cho YS1, Choe YS1, Kim BT1, Lee KH1.

Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life

Kim IR1¹, Kim SH2, Ok ON3, Kim SH4, Lee S5, Choi E6, Kim SJ7, Yoon DH8, Lee MH9.

Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma

Kim HS1¹, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase

Kwong YL1¹, Chan TSY1, Tan D2,3, Kim SJ4, Poon LM5, Mow B6, Khong PL7, Loong F8, Au-Yeung R8, Iqbal J9, Phipps C2,3, Tse E1.

The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP

Jung H1¹,2, Yoo HY3, Lee SH3, Shin S4, Kim SC1, Lee S1, Joung JG1, Nam JY1,3, Ryu D1,3, Yun JW1,5, Choi JK2, Ghosh A5, Kim KK5, Kim SJ6, Kim WS6, Park WY1, Ko YH4.

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm

Yoon N1¹, Ahn S2, Yong Yoo H3, Jin Kim S4, Seog Kim W4, Hyeh Ko Y5.

Unmet needs of non-Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health-related quality of life

Kim SH1¹, Lee S2, Kim SH3, Ok ON4, Kim IR5, Choi E1, Kang YK6, Kim SJ7, Lee MH8.

Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation

Lee MH1¹, Jang JH2, Min HJ3, Jang HI2, Nah JH2, Lyu CJ4, Han KS5, Won JH6, Lee YH7, Chong SY8, Mun YC9, Lee WS10, Kim SJ11, Kim I12.

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Hong JY1¹, Ryu KJ2, Park C3, Hong M4, Ko YH5, Kim WS6, Kim SJ2,6.

Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-kappa B and Btk

Kim JH¹, Kim WS, Hong JY, Ryu KJ, Kim SJ, Park C

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma

Ryu KJ1¹, Park C2, Hong M3, Ko YH4, Kim WS5, Kim SJ1,5.

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma

Maeng CH1¹, Ko YH2, Lim DH3, Kang ES4, Choi JY5, Kim WS6, Kim SJ6,7.

Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression

Son SM1¹, Ha SY1, Yoo HY2,3, Oh D4, Kim SJ3,5, Kim WS3,5, Ko YH1,3.

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma

Park HY1¹,2, Lee SB3, Yoo HY4, Kim SJ5, Kim WS5, Kim JI1, Ko YH2.

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)

Yoon DH1¹, Kim SJ2, Jeong SH3, Shin DY4, Bae SH5, Hong J6, Park SK7, Yhim HY8, Yang DH9, Lee H10, Kang HJ11, Lee MH12, Eom HS10, Kwak JY8, Lee JH6, Suh C1, Kim WS2.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era

Seo S1¹, Hong JY1, Yoon S1,2, Yoo C1, Park JH1, Lee JB3, Park CS4, Huh J5, Lee Y5, Kim KW6, Ryu JS7, Kim SJ8, Kim WS8, Yoon DH1, Suh C1.

Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.

Kim SJ1¹,2, Kim WS3.

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma

Jung KS1¹,2, Cho SH2, Kim SJ1, Ko YH3, Kim WS4.

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study

Kim SJ1¹, Hong JS2, Chang MH3, Kim JA4, Kwak JY5, Kim JS6, Yoon DH7, Lee WS8, Do YR9, Kang HJ10, Eom HS11, Park Y12, Won JH13, Mun YC14, Kim HJ15, Kwon JH16, Kong JH17, Oh SY18, Lee S19, Bae SH20, Yang DH21, Jun HJ22, Kim YS23, Yun HJ24, Lee SI25, Kim MK26, Park EK27, Kim WS1, Suh C7.

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis

Kim SJ1¹, Shin HT2, Lee HO2, Kim NK2, Yun JW2, Hwang JH3, Kim K1, Park WY2.

Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma

Song HN1¹, Kim SJ, Ko YH, Kim WS.

Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen

Jung SH1¹, Cho MS1, Kim HK2, Kim SJ2, Kim K3, Cheong JW4, Kim SJ4, Kim JS4, Ahn JS1, Kim YK1, Yang DH1, Kim HJ1, Lee JJ5; Korean Multiple Myeloma Working Party (KMMWP).

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker

Ryu D1¹,2, Kim HJ3, Joung JG1, Lee HO1,4, Bae JS1, Kim SJ5, Kim H5, Park WY1,2,4, Kim K5.

CD79B limits response of diffuse large B cell lymphoma to ibrutinib

Kim JH1¹, Kim WS1,2, Ryu K1, Kim SJ1,2, Park C1.

Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL

Lim SH1¹, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.

Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.

Yoo HY1¹, Kim P2, Kim WS3, Lee SH1, Kim S4, Kang SY5, Jang HY6, Lee JE6, Kim J7, Kim SJ3, Ko YH8, Lee S9.

Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma

Yoo HY1¹, Kim P2, Kim WS3, Lee SH4, Kim S5, Kang SY6, Jang HY7, Lee JE7, Kim J8, Kim SJ3, Ko YH9, Lee S10.

Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma

Shin SY1¹,2, Lee ST2,3, Kim HJ2, Oh YL4, Kim SJ5, Kim WS5, Kim SH6.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy

Maeng CH1¹,2, Ahn SW3, Ryu SY3, Han S3, Ko YH4, Ji JH5, Kim WS2, Kim SJ2.

The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea

Lee HS1¹, Min CK2, Lee JJ3, Kim K4, Kim SJ4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13, Lee MH14

Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior

Hong M1¹,2, Lee T1, Young Kang S1, Kim SJ3, Kim W3, Ko YH1.

Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis

Shin DY1¹, Kim SJ2, Yoon DH3, Park Y4, Kong JH5, Kim JA6, Kim BS7, Kim HJ8, Won JH9, Park SK10, Kim WS11.

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

Kim SJ1¹, Shin DY2, Kim JS3, Yoon DH4, Lee WS5, Lee H6, Do YR7, Kang HJ2, Eom HS6, Ko YH8, Lee SH9, Yoo HY10, Hong M11, Suh C4, Kim WS12.

L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Jung KS1¹,2, Cho SH2, Kim SJ1, Ko YH3, Kang ES4, Kim WS5.

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Kim SJ1¹, Yoon DH2, Jaccard A3, Chng WJ4, Lim ST5, Hong H6, Park Y7, Chang KM8, Maeda Y9, Ishida F10, Shin DY11, Kim JS12, Jeong SH13, Yang DH14, Jo JC15, Lee GW16, Choi CW17, Lee WS18, Chen TY19, Kim K20, Jung SH20, Murayama T21, Oki Y22, Advani R23, d'Amore F24, Schmitz N25, Suh C2, Suzuki R26, Kwong YL27, Lin TY6, Kim WS28.

Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability

Kim SM1¹, Park S1, Oh DR2, Ahn YC2, Ko YH3, Kim SJ1, Kim WS4.

Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin

Kim SJ1¹, Kim JH2, Ki CS3, Ko YH4, Kim JS5, Kim WS6.

Clonal relationships in recurrent B-cell lymphomas

Lee SE1¹, Kang SY2, Yoo HY3, Kim SJ4, Kim WS4, Ko YH2.

The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma

Ham JS1¹, Kim SJ1, Choi JY2, Hyun SH2, Choi SK3, Kim HS1, Lim SH1, Lee JY1, Jung SH3, Ko YH4, Kim WS1.

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism

Lim SH1¹, Woo SY2, Kim S2, Ko YH3, Kim WS1, Kim SJ1.

Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis

Lim SH1¹, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.

Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement

Lee MY¹, Kim HS, Lee JY, Lim SH, Kang ES, Ko YH, Kim SJ, Kim WS.

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

Park S1¹, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.

Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma

Shin SY1¹, Lee ST1, Kim HJ1, Kim SJ2, Kim K2, Kang ES1, Kim SH1.

A subset of CD45+/CD19-cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma

Kim SM1¹, Lee ST2,3, Ryu KJ4, Kim HJ2, Kim SH2, Ko YH5, Kim WS1, Kim SJ1,6.

A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients

Lee SH1¹, Kim JS1, Kim J2, Kim SJ3, Kim WS3, Lee S2, Ko YH4, Yoo HY5.

Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Oh D1¹, Ahn YC2, Kim SJ3, Kim WS3, Ko YH4.

Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy

Lee JY1¹, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma

Park S1¹, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma: Consortium for Improving Survival of Lymphoma (CISL) study

Koh MS1¹, Kim WS2, Kim SJ2, Oh SY3, Yoon DH4, Lee SI5, Hong J6, Song MK7, Shin HJ7, Kwon JH8, Kim HJ8, Do YR9, Suh C10, Kim HJ1.

Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

Cho HJ1¹, Jang MS2, Hong SD2, Kim SJ3, Ahn YC4, Oh D4, Ko YH5, Kim HY2, Dhong HJ2, Chung SK2, Kim WS3.

KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.

Epstein - Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update

Hong JY1¹, Ko YH, Kim SJ, Kim WS.

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

Yhim HY1¹, Kim JS2, Mun YC3, Moon JH4, Chae YS4, Park Y5, Jo JC6, Kim SJ7, Yoon DH8, Cheong JW2, Kwak JY1, Lee JJ9, Kim WS7, Suh C8, Yang DH10; Consortium for Improving Survival of Lymphoma Study.

Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines

Kim DS1¹, Kang KW, Lee SR, Park Y, Sung HJ, Kim SJ, Choi CW, Kim BS.

Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type

Lee S1¹, Park HY2, Kang SY3, Kim SJ4, Hwang J2, Lee S5, Kwak SH6, Park KS6,7, Yoo HY5, Kim WS4, Kim JI1,2,8, Ko YH3.

Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience

Lim AY1¹, Lee JH1, Jung KS1, Gwag HB1, Kim do H1, Kim SJ1, Lee GY1, Kim JS2, Kim HJ3, Lee SY3, Lee JE1, Jeon ES1, Kim K1.

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis

Park S1¹, Kang CI2, Chung DR2, Peck KR2, Kim WS1, Kim SJ1.

Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma

Lim do H1¹, Kim WS2, Kim SJ3, Yoo HY4, Ko YH5.

Integrated Copy Number and Gene Expression Profiling Analysis of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma

Yoon H1¹, Park S, Ju H, Ha SY, Sohn I, Jo J, Do IG, Min S, Kim SJ, Kim WS, Yoo HY, Ko YH.

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients

Kim SJ1¹,2, Ryu KJ3, Hong M4, Ko YH5, Kim WS6.

Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation

Jeong SH1¹, Moon JH, Kim JS, Yang DH, Park Y, Cho SG, Kwak JY, Eom HS, Won JH, Hong JS, Oh SY, Lee HS, Kim SJ.

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis

Hong J1¹, Kim SJ2, Ahn JS3, Song MK4, Kim YR5, Lee HS6, Yhim HY7, Yoon DH8, Kim MK9, Oh SY10, Park Y11, Mun YC12, Do YR13, Ryoo HM14, Lee JJ3, Lee JH1, Kim WS2, Suh C8.

Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma

Lee GW1¹, Go SI, Kim SH, Hong J, Kim YR, Oh S, Kim SY, Do YR, Lee H, Lee SI, Bae SH, Oh SY, Song MK, Lee WS, Lee B, Kim JS, Kim MK, Kang HJ, Ahn JS, Yhim HY, Kim HJ, Kim SJ, Kim WS, Suh C; Consortium for Improving Survival of Lymphoma (CISL) study group.

The t(11;14)(q13;q32) Trans location as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma

Shin HJ1¹, Kim K2, Lee JJ3, Song MK1, Lee EY4, Park SH4, Kim SH5, Jang MA5, Kim SJ6, Chung JS1.

The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma

Hong JY1¹, Hong ME2, Choi MK3, Chang W4, Do IG5, Jo JS5, Jung SH6, Park S7, Kim SJ7, Ko YH2, Kim WS8.

Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator

Kim SJ1¹, Hong M2, Do IG2, Lee SH3, Ryu KJ4, Yoo HY5, Hong JY6, Ko YH2, Kim WS7.

EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity

Hong JY1¹, Yoon DH2, Suh C2, Huh J3, Do IG4, Sohn I4, Jo J4, Jung SH5, Hong ME6, Yoon H6, Ko YH6, Kim SJ7, Kim WS8.

Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea

Kim MJ1¹, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS.

Asp58Ala is the Predominant Mutation of the TTR Gene in Korean Patients with Hereditary Transthyretin-Related Amyloidosis

Jang MA1¹, Lee GY, Kim K, Kim SJ, Kim JS, Lee SY, Kim HJ, Jeon ES.

Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma

Yoo KH1¹, Lee JY, Lim SH, Ko YH, Kim SJ, Kim WS.

Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients

Kim SJ1¹, Park S, Kang ES, Choi JY, Lim do H, Ko YH, Kim WS.

Simultaneous Occurrence of Angioimmunoblastic T-cell Lymphoma and Plasma Cell Leukemia

Jang MA1¹, Lee ST1, Kim HJ1, Kim S2, Kim SH1.

Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis

Lee JY1¹, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study

Kim SJ1¹, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, Nam TK, Lee SW, Ahn YC, Suh C, Kim WS.

Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience

Lee KH1¹, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma

Shin HJ1¹, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.

Spinal cord compression in multiple myeloma: a single center experience

Jung HA1¹, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.

Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients

Cho J1¹, Kang D, Lee JY, Kim K, Kim SJ.

Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study

Ahn SY1¹, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party.

Brentuximab vedotin for relapsed or refractory CD30+Hodgkin lymphoma: a multicenter analysis from Asia

Yang QM1¹, Hong JY2, Ko YH3, Lin SY4, Au WY4, Choi MK5, Park S6, Kim SJ6, Kim WS6.

Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma

Chang WJ1¹, Ko YH, Kim SJ, Kim WS.

Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement

Park S1¹, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

Chang WJ¹, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ, Kim K.

Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy

Yoon YK1¹, Kim MJ, Sohn JW, Kim HS, Choi YJ, Kim JS, Kim ST, Park KH, Kim SJ, Kim BS, Shin SW, Kim YH, Park Y.

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Kim SM1¹, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein

Ha JM1¹, Kim E, Lee WJ, Hwang JW, Yune S, Ko YH, Choi JY, Kim SJ, Kim WS.

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

Eom KS1¹, Kim SJ2, Lee JJ3, Suh C4, Kim JS5, Yoon SS6, Kim BS7, Kang HJ8, Choi YJ9, Kim CS10, Kim YS11, Kwak JY12, Kim YJ1, Joo YD13, Mun YC14, Jo DY15, Park JS16, Park CY17, Kim SH18, Min CK1.

Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness

Lee GY1¹, Kim K2, Choi JO1, Kim SJ2, Kim JS3, Choe YH4, Grogan MA5, Jeon ES6.

Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients

Park S1¹, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma

Yoo HY1¹, Sung MK2, Lee SH3, Kim S4, Lee H4, Park S5, Kim SC5, Lee B5, Rho K6, Lee JE6, Cho KH7, Kim W4, Ju H8, Kim J4, Kim SJ9, Kim WS9, Lee S4, Ko YH10.

Central nervous system multiple myeloma: a different cytogenetic profile

Chang WJ1¹, Kim SJ, Kim K.

CD798 and MYD88 mutations in diffuse Large B-cell Lymphoma

Kim Y1¹, Ju H2, Kim DH3, Yoo HY4, Kim SJ5, Kim WS5, Ko YH6.

Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP

Kim YS1¹, Ji JH, Ko YH, Kim SJ, Kim WS.

Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay

Kim SJ1¹, Sohn I, Do IG, Jung SH, Ko YH, Yoo HY, Paik S, Kim WS.

Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP

Park S1¹, Han B, Cho JW, Woo SY, Kim S, Kim SJ, Kim WS.

Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia

Jung HA1¹, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases

Hong JY1¹, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS.

Primary Follicular Lymphoma in a Male Breast: A Case Report

Jung SP1¹, Han KM2, Kim SJ3, Nam SJ4, Bae JW1, Lee JE4.

Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients

Kim K1¹, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP).

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

Park S1¹, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.

Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea

Hong JY1¹, Kim HJ, Ko YH, Choi JY, Jung CW, Kim SJ, Kim WS.

A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas

Kim SJ1¹, Kang HJ, Kim JS, Eom HS, Huh J, Ko YH, Lee J, Yim DS, Lee SY, Park WS, Yang WI, Lee SS, Suh C, Kim WS.

Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea

Kim SJ1¹, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

Kim SJ1¹, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

Kim SJ1¹, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, Hong XN, Suzuki R, Kang HJ, Won JH, Chng WJ, Kwong YL, Suh C, Song YQ, Zhu J, Tay K, Lim ST, Suzumiya J, Lin TY, Kim WS; Asia Lymphoma Study Group.

Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines

Tan D1¹, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, Kwong YL.

Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation

Choi MK1¹, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS.

Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia

Lee SM1¹, Lee WS, Shin HJ, Lee JJ, Sohn SK, Moon JH, Eom HS, Won JH, Lee KH, Lee JH, Kim DY, Yoon SS, Kim I, Jung CW, Kim SJ, Kim H, Lee JH, Ryoo HM, Lee GW, Kim SH, Mun YC, Kim MK, Joo YD; Korean Society of Hematology Adult ALL working party.

Unusual Presentation of Ewing Sarcoma in the Adrenal Gland: A Secondary Malignancy from a Survivor of Burkitt Lymphoma

Lim SH1¹, Lee JY, Lee JY, Kim JH, Choi KH, Hyun JY, Ko YH, Lee J, Kim SJ, Kim WS.

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ohmachi K1¹, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M.

Isolation of Side Population Cells in B-Cell Non-Hodgkin's Lymphomas

Lee MR1¹, Ju HJ, Kim BS, Ko YH, Kim WS, Kim SJ.

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

Kim SJ1¹, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators.

Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study

Jung HA1¹, Park S, Cho JH, Kim S, Ko YH, Kim SJ, Kim WS.

Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal A study by the Consortium for Improving Survival of Lymphoma (CISL)

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Lee SI, Kang HJ, Choi CW, Park J, Song MK, Kim HJ, Kwon JH, Kwak JY, Bae SH, Park BB, Do YR, Lee HS, Jeong SH, Suh C, Kim HJ.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group

Kwong YL1¹, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS.

Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population

Park LC1¹, Woo SY, Kim S, Jeon H, Ko YH, Kim SJ, Kim WS.

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Kim YR1¹, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, Oh SY, Lee S, Park EK, Jang JS, Lee WS, Lee HW, Eom H, Ahn JS, Jeong JH, Baek SK, Kim SJ, Kim WS, Suh C.

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

Kim SJ1¹, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH, Reksodiputro AH, Lim ST, Cheng AL, Kim WS, Kwong YL.

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy

Yhim HY1¹, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY.

Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group

Tse E1¹, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, Chng WJ, Lim ST, Kim WS, Kwong YL.

Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma

Yang DH1¹, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh C, Lee JJ.

Endoscopic Findings in Mantle Cell Lymphoma with Gastrointestinal Tract Involvement

Kim JH1¹, Jung HW, Kang KJ, Min BH, Lee JH, Chang DK, Kim YH, Son HJ, Rhee PL, Kim JJ, Rhee JC, Kim SJ, Kim WS, Ko YH, Kim JY.

Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

Won YW1¹, Kwon JH, Lee SI, Oh SY, Kim WS, Kim SJ, Won JH, Kim KH, Park SK, Kim JS, Suh C, Yoon DH, Park JS, Kim MK, Kim H, Kang HJ, Mun YC, Kwak JY, Kim HJ, Eom HS.

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

Kim SJ1¹, Kim K, Park Y, Kim BS, Huh J, Ko YH, Park K, Suh C, Kim WS.

Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease - Consortium for Improving Survival of Lymphoma Study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Kang HJ, Song MK, Kim HJ, Kwon JH, Kwak JY, Park BB, Do YR, Jeong SH, Suh C.

Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value

Lee HY¹, Kim SJ, Kim K, Ko YH, Kim WS.

B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy

Kim SJ1¹, Won JH.

Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma

Park Y1¹, Choi YJ, Park SJ, Lee SR, Sung HJ, Park KH, Kim SJ, Choi CW, Jung KY, Kim BS.

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Kim YR1¹, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, Cheong JW, Min YH.

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)

Kim SJ1¹, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS.

Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma

Kim SJ1¹, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C.

Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study

Kim SJ1¹, Kim K, Do YR, Bae SH, Yang DH, Lee JJ.

Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients

Kim MK1¹, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH; Korean Multiple Myeloma Working Party.

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone

Kim SJ1¹, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS.

Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy

Yi JH¹, Kim SJ, Ko YH, Kim WS.

Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis

Kim JA1¹, Kim SJ, Do IG, Jin J, Nam DH, Ko YH, Kim K, Kim WS.

Prognostic Significance of Serum Vascular Endothelial Growth Factor Per Platelet Count in Unresectable Advanced Gastric Cancer Patients

Seo HY1¹, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS.

Treatment of localized extranodal NK/T cell lymphoma, nasal type

Kim SJ1¹, Kim WS.

GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization

Koh Y1¹, Kim DY, Park SH, Jung SH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Shin HJ, Kim SH, Song HS, Chung J, Kim I, Yoon SS, Kim BK, Shin SH, Chung YJ, Park S.

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

Kim SJ1¹, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH.

Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ.

Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate

Yang KH1¹, Park SY, Park SW, Lee SH, Han SB, Jung WK, Kim SJ.

Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma

Kim BJ1¹, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, Cho SC, So YT, Oh SY, Kim SJ.

Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ.

Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea

Won YW1¹, Kim SJ, Kim K, Ko YH, Kim WS.

Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report

Yun J1¹, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, Kim MK, Kwak JY, Kim WS, Suh C.

F-18-FDG uptake and its clinical relevance in primary gastric lymphoma

Yi JH1¹, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS.

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

Yhim HY1¹, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY.

A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Kim ST1¹, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.

When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type

Kim SJ1¹, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS.

Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission

Au WY¹, Kim SJ, Yiu HH, Ngan RK, Loong F, Kim WS, Kwong YL.

Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma

Lee SC¹, Kim SJ, Lee DH, Kim WS, Suh C, Won JH.

Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial

Oh SY1¹, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C.

Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients

Ahn HK1¹, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS.

Molecular cytogenetic analysis of Korean patients with Waldenstrom macroglobulinemia

Bang SM1¹, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, Cho SR, Kim HC, Song J, Kim JS, Kim KH, Lee JH, Lee JJ, Shin MG, Suh C, Chi HS, Oh DY, Won JH, Kim HJ, Yoon SS, Lee DS; Korean Multiple Myeloma Working Party (KMMWP).

The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease

Park Y1¹, Kim DS, Park SJ, Seo HY, Lee SR, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.

Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer

Kim SJ1¹, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ.

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

Koh Y1¹, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party.

Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Choi ER1¹, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.

Primary Angiosarcoma of the Pulmonary Trunk Mimicking Pulmonary Thromboembolism

Kim JB1¹, Kim SH, Lim SY, Roh SY, Cho GY, Song HJ, Park S, Lee J, Kim SJ.

Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

Kim SJ1¹, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS.

Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience

Yun J1¹, Kim SJ, Kim JA, Kong JH, Lee SH, Kim K, Ko YH, Kim WS.

Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea

Choi MK1¹, Jun HJ, Lee SY, Kim KH, Lim do H, Kim K, Ko YH, Kim WS, Kim SJ.

Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry

Kim SJ1¹, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea

Chang MH1¹, Kim SJ, Kim K, Oh SY, Lee DH, Huh J, Ko YH, Choi CW, Yang DH, Won JH, Kim WS, Suh C.

Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy

Seo HY1¹, Kim EB, Kim JW, Shin BK, Kim SJ, Kim BS.

Rituximab-induced acute thrombocytopenia: a case report and review of the literature

Yi JH1¹, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS.

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study

Kim SJ¹, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS.

Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas

Kim SJ1¹, Lee SJ, Sung HJ, Choi IK, Choi CW, Kim BS, Kim JS, Yu W, Hwang HS, Kim IS.

Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy

Kim SJ1¹, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS.

Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: Does it have a prognostic value

Park Y¹, Kim SJ, Lee SJ, Kim BS.

Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma

Kim SJ1¹, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, Nam SH, Kwon JH, Kim HJ, Sohn SK, Won JH, Lee JH, Suh C, Yoon SS, Kim HJ, Kim I, Do YR, Lee WS, Joo YD, Shin HJ; Korean Multiple Myeloma Working Party.